John Erby Wilkinson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
John Erby Wilkinson has a total of 163 co-authors. Here are the top co-authors by number of shared publications:
- David A. Tuveson
Cold spring harbor laboratory, cold spring harbor, USA
22 shared publications - Adrian R. Krainer
Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA
15 shared publications - Youngkyu Park
Cold Spring Harbor Laboratory, Cold Spring Harbor, New York
13 shared publications - Kuan-Ting Lin
Cold Spring Harbor Laboratory, Cold Spring Harbor, New York
12 shared publications - Ledong Wan
Department of Pharmacological Sciences, State University of New York at Stony Brook, Stony Brook, NY 11794, USA
12 shared publications - Mads A. Jensen
Cold Spring Harbor Laboratory, Cold Spring Harbor, New York
12 shared publications
Latest Publications
- Open Access
Exon-Skipping Antisense Oligonucleotides for H3.3K27M-Altered Diffuse Midline Glioma Therapy
Diffuse midline gliomas (DMGs) are a deadly class of pediatric high-grade brain cancers. Approximately 80% of pontine DMGs feature a dominant, somatic, heterozygous point mutation in the non-canonical histone H3.3-coding gene H3-3A . This dominant-negative mutation replaces lysine 27 with methionine (K27M) and prevents global K27 di- and tri-methylation of all wild-type histone H3 proteins. We aimed to target the H3.3K27M onco-histone pre-mRNA with splice-switching antisense oligonucleotides (ASOs) designed to promote skipping of H3-3A exon 2, as this constitutive exon comprises both the K27M mutation and the natural in-frame start codon of the gene. The lead ASO identified in a systematic screen specifically induced H3-3A exon 2 skipping, did not affect expression or splicing of the paralog gene H3-3B —which also encodes histone H3.3—and restored global H3K27me3 marks in patient-derived DMG cells grown as neurospheres. In a patient-derived orthotopic xenograft tumor mouse model, the lead ASO reduced proliferation and extended survival. Our results show the potential of exon-skipping ASOs targeting H3-3A exon 2 as a therapeutic option for H3.3K27M-altered DMG. More generally, they exemplify the strategy of using ASOs to induce skipping of a constitutive exon to effectively achieve gene downregulation.
Open AccessExon-Skipping Antisense Oligonucleotides for H3.3K27M-Altered Diffuse Midline Glioma Therapy
Diffuse midline gliomas (DMGs) are a deadly class of pediatric high-grade brain cancers. Approximately 80% of pontine DMGs feature a dominant, somatic, heterozygous point mutation in the non-canonical histone H3.3-coding gene H3-3A . This dominant-negative mutation replaces lysine 27 with methionine (K27M) and prevents global K27 di- and tri-methylation of all wild-type histone H3 proteins. We aimed to target the H3.3K27M onco-histone pre-mRNA with splice-switching antisense oligonucleotides (ASOs) designed to promote skipping of H3-3A exon 2, as this constitutive exon comprises both the K27M mutation and the natural in-frame start codon of the gene. The lead ASO identified in a systematic screen specifically induced H3-3A exon 2 skipping, did not affect expression or splicing of the paralog gene H3-3B —which also encodes histone H3.3—and restored global H3K27me3 marks in patient-derived DMG cells grown as neurospheres. In a patient-derived orthotopic xenograft tumor mouse model, the lead ASO reduced proliferation and extended survival. Our results show the potential of exon-skipping ASOs targeting H3-3A exon 2 as a therapeutic option for H3.3K27M-altered DMG. More generally, they exemplify the strategy of using ASOs to induce skipping of a constitutive exon to effectively achieve gene downregulation.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1-S11 and Table S1 from Splicing Factor SRSF1 Promotes Pancreatitis and KRASG12D-Mediated Pancreatic Cancer
Figure S1. Elevated SRSF1 induces pancreatitis and is associated with its duration. Figure S2. Elevated SRSF1 predicts poor PDAC clinical prognosis and is associated with PDAC progression. Figure S3. SRSF1 accelerates KRASG12D-mediated PDAC tumorigenesis. Figure S4. SRSF1 loss delays KRASG12D-mediated PDAC initiation. Figure S5. Opposite patterns of pathway enrichment by KRASG12D mutation versus SRSF1 upregulation. Figure S6. Recombination and activation of KrasG12D allele in pancreas cells from KC mice. Figure S7. KSC and KPSC mice exhibit a hyper-activated MAPK pathway, suppression of which diminished SRSF1-induced pancreatitis. Figure S8. Decreased SRSF1 expression perturbs MAPK signaling. Figure S9. MYC promotes SRSF1 expression in PDAC. Figure S10. SRSF1 regulates IL1R1 alternative splicing and expression. Figure S11. Knockout of Il1r1 rescues SRSF1-induced pancreatitis. Table S1. Oligonucleotides for PCR and short hairpin RNAs.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1-S11 and Table S1 from Splicing Factor SRSF1 Promotes Pancreatitis and KRASG12D-Mediated Pancreatic Cancer
Figure S1. Elevated SRSF1 induces pancreatitis and is associated with its duration. Figure S2. Elevated SRSF1 predicts poor PDAC clinical prognosis and is associated with PDAC progression. Figure S3. SRSF1 accelerates KRASG12D-mediated PDAC tumorigenesis. Figure S4. SRSF1 loss delays KRASG12D-mediated PDAC initiation. Figure S5. Opposite patterns of pathway enrichment by KRASG12D mutation versus SRSF1 upregulation. Figure S6. Recombination and activation of KrasG12D allele in pancreas cells from KC mice. Figure S7. KSC and KPSC mice exhibit a hyper-activated MAPK pathway, suppression of which diminished SRSF1-induced pancreatitis. Figure S8. Decreased SRSF1 expression perturbs MAPK signaling. Figure S9. MYC promotes SRSF1 expression in PDAC. Figure S10. SRSF1 regulates IL1R1 alternative splicing and expression. Figure S11. Knockout of Il1r1 rescues SRSF1-induced pancreatitis. Table S1. Oligonucleotides for PCR and short hairpin RNAs.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Data from Splicing Factor SRSF1 Promotes Pancreatitis and KRASG12D-Mediated Pancreatic Cancer
Inflammation is strongly associated with pancreatic ductal adenocarcinoma (PDAC), a highly lethal malignancy. Dysregulated RNA splicing factors have been widely reported in tumorigenesis, but their involvement in pancreatitis and PDAC is not well understood. Here, we report that the splicing factor SRSF1 is highly expressed in pancreatitis, PDAC precursor lesions, and tumors. Increased SRSF1 is sufficient to induce pancreatitis and accelerate KRASG12D-mediated PDAC. Mechanistically, SRSF1 activates MAPK signaling—partly by upregulating interleukin 1 receptor type 1 (IL1R1) through alternative-splicing-regulated mRNA stability. Additionally, SRSF1 protein is destabilized through a negative feedback mechanism in phenotypically normal epithelial cells expressing KRASG12D in mouse pancreas and in pancreas organoids acutely expressing KRASG12D, buffering MAPK signaling and maintaining pancreas cell homeostasis. This negative feedback regulation of SRSF1 is overcome by hyperactive MYC, facilitating PDAC tumorigenesis. Our findings implicate SRSF1 in the etiology of pancreatitis and PDAC, and point to SRSF1-misregulated alternative splicing as a potential therapeutic target.Significance:We describe the regulation of splicing factor SRSF1 expression in the context of pancreas cell identity, plasticity, and inflammation. SRSF1 protein downregulation is involved in a negative feedback cellular response to KRASG12D expression, contributing to pancreas cell homeostasis. Conversely, upregulated SRSF1 promotes pancreatitis and accelerates KRASG12D-mediated tumorigenesis through enhanced IL1 and MAPK signaling.This article is highlighted in the In This Issue feature, p. 1501
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Splicing Factor SRSF1 Promotes Pancreatitis and KRASG12D-Mediated Pancreatic Cancer
Inflammation is strongly associated with pancreatic ductal adenocarcinoma (PDAC), a highly lethal malignancy. Dysregulated RNA splicing factors have been widely reported in tumorigenesis, but their involvement in pancreatitis and PDAC is not well understood. Here, we report that the splicing factor SRSF1 is highly expressed in pancreatitis, PDAC precursor lesions, and tumors. Increased SRSF1 is sufficient to induce pancreatitis and accelerate KRASG12D-mediated PDAC. Mechanistically, SRSF1 activates MAPK signaling—partly by upregulating interleukin 1 receptor type 1 (IL1R1) through alternative-splicing-regulated mRNA stability. Additionally, SRSF1 protein is destabilized through a negative feedback mechanism in phenotypically normal epithelial cells expressing KRASG12D in mouse pancreas and in pancreas organoids acutely expressing KRASG12D, buffering MAPK signaling and maintaining pancreas cell homeostasis. This negative feedback regulation of SRSF1 is overcome by hyperactive MYC, facilitating PDAC tumorigenesis. Our findings implicate SRSF1 in the etiology of pancreatitis and PDAC, and point to SRSF1-misregulated alternative splicing as a potential therapeutic target.Significance:We describe the regulation of splicing factor SRSF1 expression in the context of pancreas cell identity, plasticity, and inflammation. SRSF1 protein downregulation is involved in a negative feedback cellular response to KRASG12D expression, contributing to pancreas cell homeostasis. Conversely, upregulated SRSF1 promotes pancreatitis and accelerates KRASG12D-mediated tumorigenesis through enhanced IL1 and MAPK signaling.This article is highlighted in the In This Issue feature, p. 1501
- Top Cited Papers
- 25 October 2024
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 386 (6720) , eadk9167
Dietary pro-oxidant therapy by a vitamin K precursor targets PI 3-kinase VPS34 function
Men taking antioxidant vitamin E supplements have increased prostate cancer (PC) risk. However, whether pro-oxidants protect from PC remained unclear. In this work, we show that a pro-oxidant vitamin K precursor [menadione sodium bisulfite (MSB)] suppresses PC progression in mice, killing cells through an oxidative cell death: MSB antagonizes the essential class III phosphatidylinositol (PI) 3-kinase VPS34—the regulator of endosome identity and sorting—through oxidation of key cysteines, pointing to a redox checkpoint in sorting. Testing MSB in a myotubular myopathy model that is driven by loss of MTM1 —the phosphatase antagonist of VPS34—we show that dietary MSB improved muscle histology and function and extended life span. These findings enhance our understanding of pro-oxidant selectivity and show how definition of the pathways they impinge on can give rise to unexpected therapeutic opportunities.
- 25 October 2024
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 386 (6720) , eadk9167
Top Cited PapersDietary pro-oxidant therapy by a vitamin K precursor targets PI 3-kinase VPS34 function
Men taking antioxidant vitamin E supplements have increased prostate cancer (PC) risk. However, whether pro-oxidants protect from PC remained unclear. In this work, we show that a pro-oxidant vitamin K precursor [menadione sodium bisulfite (MSB)] suppresses PC progression in mice, killing cells through an oxidative cell death: MSB antagonizes the essential class III phosphatidylinositol (PI) 3-kinase VPS34—the regulator of endosome identity and sorting—through oxidation of key cysteines, pointing to a redox checkpoint in sorting. Testing MSB in a myotubular myopathy model that is driven by loss of MTM1 —the phosphatase antagonist of VPS34—we show that dietary MSB improved muscle histology and function and extended life span. These findings enhance our understanding of pro-oxidant selectivity and show how definition of the pathways they impinge on can give rise to unexpected therapeutic opportunities.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Data from Splicing Factor SRSF1 Promotes Pancreatitis and KRASG12D-Mediated Pancreatic Cancer
Inflammation is strongly associated with pancreatic ductal adenocarcinoma (PDAC), a highly lethal malignancy. Dysregulated RNA splicing factors have been widely reported in tumorigenesis, but their involvement in pancreatitis and PDAC is not well understood. Here, we report that the splicing factor SRSF1 is highly expressed in pancreatitis, PDAC precursor lesions, and tumors. Increased SRSF1 is sufficient to induce pancreatitis and accelerate KRASG12D-mediated PDAC. Mechanistically, SRSF1 activates MAPK signaling—partly by upregulating interleukin 1 receptor type 1 (IL1R1) through alternative-splicing-regulated mRNA stability. Additionally, SRSF1 protein is destabilized through a negative feedback mechanism in phenotypically normal epithelial cells expressing KRASG12D in mouse pancreas, and in pancreas organoids acutely expressing KRASG12D, buffering MAPK signaling and maintaining pancreas-cell homeostasis. This negative-feedback regulation of SRSF1 is overcome by hyperactive MYC, facilitating PDAC tumorigenesis. Our findings implicate SRSF1 in the etiology of pancreatitis and PDAC, and point to SRSF1-misregulated alternative splicing as a potential therapeutic target.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Splicing Factor SRSF1 Promotes Pancreatitis and KRASG12D-Mediated Pancreatic Cancer
Inflammation is strongly associated with pancreatic ductal adenocarcinoma (PDAC), a highly lethal malignancy. Dysregulated RNA splicing factors have been widely reported in tumorigenesis, but their involvement in pancreatitis and PDAC is not well understood. Here, we report that the splicing factor SRSF1 is highly expressed in pancreatitis, PDAC precursor lesions, and tumors. Increased SRSF1 is sufficient to induce pancreatitis and accelerate KRASG12D-mediated PDAC. Mechanistically, SRSF1 activates MAPK signaling—partly by upregulating interleukin 1 receptor type 1 (IL1R1) through alternative-splicing-regulated mRNA stability. Additionally, SRSF1 protein is destabilized through a negative feedback mechanism in phenotypically normal epithelial cells expressing KRASG12D in mouse pancreas, and in pancreas organoids acutely expressing KRASG12D, buffering MAPK signaling and maintaining pancreas-cell homeostasis. This negative-feedback regulation of SRSF1 is overcome by hyperactive MYC, facilitating PDAC tumorigenesis. Our findings implicate SRSF1 in the etiology of pancreatitis and PDAC, and point to SRSF1-misregulated alternative splicing as a potential therapeutic target.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1-S11 and Table S1 from Splicing Factor SRSF1 Promotes Pancreatitis and KRASG12D-Mediated Pancreatic Cancer
Figure S1. Elevated SRSF1 induces pancreatitis and is associated with its duration. Figure S2. Elevated SRSF1 predicts poor PDAC clinical prognosis and is associated with PDAC progression. Figure S3. SRSF1 accelerates KRASG12D-mediated PDAC tumorigenesis. Figure S4. SRSF1 loss delays KRASG12D-mediated PDAC initiation. Figure S5. Opposite patterns of pathway enrichment by KRASG12D mutation versus SRSF1 upregulation. Figure S6. Recombination and activation of KrasG12D allele in pancreas cells from KC mice. Figure S7. KSC and KPSC mice exhibit a hyper-activated MAPK pathway, suppression of which diminished SRSF1-induced pancreatitis. Figure S8. Decreased SRSF1 expression perturbs MAPK signaling. Figure S9. MYC promotes SRSF1 expression in PDAC. Figure S10. SRSF1 regulates IL1R1 alternative splicing and expression. Figure S11. Knockout of Il1r1 rescues SRSF1-induced pancreatitis. Table S1. Oligonucleotides for PCR and short hairpin RNAs.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1-S11 and Table S1 from Splicing Factor SRSF1 Promotes Pancreatitis and KRASG12D-Mediated Pancreatic Cancer
Figure S1. Elevated SRSF1 induces pancreatitis and is associated with its duration. Figure S2. Elevated SRSF1 predicts poor PDAC clinical prognosis and is associated with PDAC progression. Figure S3. SRSF1 accelerates KRASG12D-mediated PDAC tumorigenesis. Figure S4. SRSF1 loss delays KRASG12D-mediated PDAC initiation. Figure S5. Opposite patterns of pathway enrichment by KRASG12D mutation versus SRSF1 upregulation. Figure S6. Recombination and activation of KrasG12D allele in pancreas cells from KC mice. Figure S7. KSC and KPSC mice exhibit a hyper-activated MAPK pathway, suppression of which diminished SRSF1-induced pancreatitis. Figure S8. Decreased SRSF1 expression perturbs MAPK signaling. Figure S9. MYC promotes SRSF1 expression in PDAC. Figure S10. SRSF1 regulates IL1R1 alternative splicing and expression. Figure S11. Knockout of Il1r1 rescues SRSF1-induced pancreatitis. Table S1. Oligonucleotides for PCR and short hairpin RNAs.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1-S11 and Table S1 from Splicing Factor SRSF1 Promotes Pancreatitis and KRASG12D-Mediated Pancreatic Cancer
Figure S1. Elevated SRSF1 induces pancreatitis and is associated with its duration. Figure S2. Elevated SRSF1 predicts poor PDAC clinical prognosis and is associated with PDAC progression. Figure S3. SRSF1 accelerates KRASG12D-mediated PDAC tumorigenesis. Figure S4. SRSF1 loss delays KRASG12D-mediated PDAC initiation. Figure S5. Opposite patterns of pathway enrichment by KRASG12D mutation versus SRSF1 upregulation. Figure S6. Recombination and activation of KrasG12D allele in pancreas cells from KC mice. Figure S7. KSC and KPSC mice exhibit a hyper-activated MAPK pathway, suppression of which diminished SRSF1-induced pancreatitis. Figure S8. Decreased SRSF1 expression perturbs MAPK signaling. Figure S9. MYC promotes SRSF1 expression in PDAC. Figure S10. SRSF1 regulates IL1R1 alternative splicing and expression. Figure S11. Knockout of Il1r1 rescues SRSF1-induced pancreatitis. Table S1. Oligonucleotides for PCR and short hairpin RNAs.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1-S11 and Table S1 from Splicing Factor SRSF1 Promotes Pancreatitis and KRASG12D-Mediated Pancreatic Cancer
Figure S1. Elevated SRSF1 induces pancreatitis and is associated with its duration. Figure S2. Elevated SRSF1 predicts poor PDAC clinical prognosis and is associated with PDAC progression. Figure S3. SRSF1 accelerates KRASG12D-mediated PDAC tumorigenesis. Figure S4. SRSF1 loss delays KRASG12D-mediated PDAC initiation. Figure S5. Opposite patterns of pathway enrichment by KRASG12D mutation versus SRSF1 upregulation. Figure S6. Recombination and activation of KrasG12D allele in pancreas cells from KC mice. Figure S7. KSC and KPSC mice exhibit a hyper-activated MAPK pathway, suppression of which diminished SRSF1-induced pancreatitis. Figure S8. Decreased SRSF1 expression perturbs MAPK signaling. Figure S9. MYC promotes SRSF1 expression in PDAC. Figure S10. SRSF1 regulates IL1R1 alternative splicing and expression. Figure S11. Knockout of Il1r1 rescues SRSF1-induced pancreatitis. Table S1. Oligonucleotides for PCR and short hairpin RNAs.
- Open Access
Metastatic site influences driver gene function in pancreatic cancer
Driver gene mutations can increase the metastatic potential of the primary tumor 1–3 , but their role in sustaining tumor growth at metastatic sites is poorly understood. A paradigm of such mutations is inactivation of SMAD4 – a transcriptional effector of TGFβ signaling – which is a hallmark of multiple gastrointestinal malignancies 4,5 . SMAD4 inactivation mediates TGFβ’s remarkable anti-to pro-tumorigenic switch during cancer progression and can thus influence both tumor initiation and metastasis 6–14 . To determine whether metastatic tumors remain dependent on SMAD4 inactivation, we developed a mouse model of pancreatic ductal adenocarcinoma (PDAC) that enables Smad4 depletion in the pre-malignant pancreas and subsequent Smad4 reactivation in established metastases. As expected, Smad4 inactivation facilitated the formation of primary tumors that eventually colonized the liver and lungs. By contrast, Smad4 reactivation in metastatic disease had strikingly opposite effects depending on the tumor’s organ of residence: suppression of liver metastases and promotion of lung metastases. Integrative multiomic analysis revealed organ-specific differences in the tumor cells’ epigenomic state, whereby the liver and lungs harbored chromatin programs respectively dominated by the KLF and RUNX developmental transcription factors, with Klf4 depletion being sufficient to reverse Smad4 ’s tumor-suppressive activity in liver metastases. Our results show how epigenetic states favored by the organ of residence can influence the function of driver genes in metastatic tumors. This organ-specific gene–chromatin interplay invites consideration of anatomical site in the interpretation of tumor genetics, with implications for the therapeutic targeting of metastatic disease.
Open AccessMetastatic site influences driver gene function in pancreatic cancer
Driver gene mutations can increase the metastatic potential of the primary tumor 1–3 , but their role in sustaining tumor growth at metastatic sites is poorly understood. A paradigm of such mutations is inactivation of SMAD4 – a transcriptional effector of TGFβ signaling – which is a hallmark of multiple gastrointestinal malignancies 4,5 . SMAD4 inactivation mediates TGFβ’s remarkable anti-to pro-tumorigenic switch during cancer progression and can thus influence both tumor initiation and metastasis 6–14 . To determine whether metastatic tumors remain dependent on SMAD4 inactivation, we developed a mouse model of pancreatic ductal adenocarcinoma (PDAC) that enables Smad4 depletion in the pre-malignant pancreas and subsequent Smad4 reactivation in established metastases. As expected, Smad4 inactivation facilitated the formation of primary tumors that eventually colonized the liver and lungs. By contrast, Smad4 reactivation in metastatic disease had strikingly opposite effects depending on the tumor’s organ of residence: suppression of liver metastases and promotion of lung metastases. Integrative multiomic analysis revealed organ-specific differences in the tumor cells’ epigenomic state, whereby the liver and lungs harbored chromatin programs respectively dominated by the KLF and RUNX developmental transcription factors, with Klf4 depletion being sufficient to reverse Smad4 ’s tumor-suppressive activity in liver metastases. Our results show how epigenetic states favored by the organ of residence can influence the function of driver genes in metastatic tumors. This organ-specific gene–chromatin interplay invites consideration of anatomical site in the interpretation of tumor genetics, with implications for the therapeutic targeting of metastatic disease.
- Open Access
- 7 July 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1-S11 and Table S1 from Splicing Factor SRSF1 Promotes Pancreatitis and KRASG12D-Mediated Pancreatic Cancer
Figure S1. Elevated SRSF1 induces pancreatitis and is associated with its duration. Figure S2. Elevated SRSF1 predicts poor PDAC clinical prognosis and is associated with PDAC progression. Figure S3. SRSF1 accelerates KRASG12D-mediated PDAC tumorigenesis. Figure S4. SRSF1 loss delays KRASG12D-mediated PDAC initiation. Figure S5. Opposite patterns of pathway enrichment by KRASG12D mutation versus SRSF1 upregulation. Figure S6. Recombination and activation of KrasG12D allele in pancreas cells from KC mice. Figure S7. KSC and KPSC mice exhibit a hyper-activated MAPK pathway, suppression of which diminished SRSF1-induced pancreatitis. Figure S8. Decreased SRSF1 expression perturbs MAPK signaling. Figure S9. MYC promotes SRSF1 expression in PDAC. Figure S10. SRSF1 regulates IL1R1 alternative splicing and expression. Figure S11. Knockout of Il1r1 rescues SRSF1-induced pancreatitis. Table S1. Oligonucleotides for PCR and short hairpin RNAs.
- 7 July 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1-S11 and Table S1 from Splicing Factor SRSF1 Promotes Pancreatitis and KRASG12D-Mediated Pancreatic Cancer
Figure S1. Elevated SRSF1 induces pancreatitis and is associated with its duration. Figure S2. Elevated SRSF1 predicts poor PDAC clinical prognosis and is associated with PDAC progression. Figure S3. SRSF1 accelerates KRASG12D-mediated PDAC tumorigenesis. Figure S4. SRSF1 loss delays KRASG12D-mediated PDAC initiation. Figure S5. Opposite patterns of pathway enrichment by KRASG12D mutation versus SRSF1 upregulation. Figure S6. Recombination and activation of KrasG12D allele in pancreas cells from KC mice. Figure S7. KSC and KPSC mice exhibit a hyper-activated MAPK pathway, suppression of which diminished SRSF1-induced pancreatitis. Figure S8. Decreased SRSF1 expression perturbs MAPK signaling. Figure S9. MYC promotes SRSF1 expression in PDAC. Figure S10. SRSF1 regulates IL1R1 alternative splicing and expression. Figure S11. Knockout of Il1r1 rescues SRSF1-induced pancreatitis. Table S1. Oligonucleotides for PCR and short hairpin RNAs.
- Open Access
- 7 July 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1-S11 and Table S1 from Splicing Factor SRSF1 Promotes Pancreatitis and KRASG12D-Mediated Pancreatic Cancer
Figure S1. Elevated SRSF1 induces pancreatitis and is associated with its duration. Figure S2. Elevated SRSF1 predicts poor PDAC clinical prognosis and is associated with PDAC progression. Figure S3. SRSF1 accelerates KRASG12D-mediated PDAC tumorigenesis. Figure S4. SRSF1 loss delays KRASG12D-mediated PDAC initiation. Figure S5. Opposite patterns of pathway enrichment by KRASG12D mutation versus SRSF1 upregulation. Figure S6. Recombination and activation of KrasG12D allele in pancreas cells from KC mice. Figure S7. KSC and KPSC mice exhibit a hyper-activated MAPK pathway, suppression of which diminished SRSF1-induced pancreatitis. Figure S8. Decreased SRSF1 expression perturbs MAPK signaling. Figure S9. MYC promotes SRSF1 expression in PDAC. Figure S10. SRSF1 regulates IL1R1 alternative splicing and expression. Figure S11. Knockout of Il1r1 rescues SRSF1-induced pancreatitis. Table S1. Oligonucleotides for PCR and short hairpin RNAs.
- 7 July 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1-S11 and Table S1 from Splicing Factor SRSF1 Promotes Pancreatitis and KRASG12D-Mediated Pancreatic Cancer
Figure S1. Elevated SRSF1 induces pancreatitis and is associated with its duration. Figure S2. Elevated SRSF1 predicts poor PDAC clinical prognosis and is associated with PDAC progression. Figure S3. SRSF1 accelerates KRASG12D-mediated PDAC tumorigenesis. Figure S4. SRSF1 loss delays KRASG12D-mediated PDAC initiation. Figure S5. Opposite patterns of pathway enrichment by KRASG12D mutation versus SRSF1 upregulation. Figure S6. Recombination and activation of KrasG12D allele in pancreas cells from KC mice. Figure S7. KSC and KPSC mice exhibit a hyper-activated MAPK pathway, suppression of which diminished SRSF1-induced pancreatitis. Figure S8. Decreased SRSF1 expression perturbs MAPK signaling. Figure S9. MYC promotes SRSF1 expression in PDAC. Figure S10. SRSF1 regulates IL1R1 alternative splicing and expression. Figure S11. Knockout of Il1r1 rescues SRSF1-induced pancreatitis. Table S1. Oligonucleotides for PCR and short hairpin RNAs.